Neurobiological Tech (NTII) | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Neurobiological Tech (NTII)

An SI Board Since September 1996

Posts	SubjectMarks	Bans	Symbol
1494	40	0	NTII

Emcee: Miles Rhyne Hoffman, CFA	Type: Unmoderated

Introduction Market Data Compact

Neurobiological Technologies is a biopharmaceutical company that develops proprietary therapeutic products based on advances in neuroscience research. The company has several products in various stages of development and testing. Its corticotropin-releasing factor (CRF) is designed to treat asthma, rheumatoid arthritis, and swelling caused by brain tumors. Its memantine is a potential neuroprotective agent that could treat neurodegenerative diseases such as AIDS-related dementia complex. Its dynorphin A and Nicosim products are being evaluated for use as analgesics for patients with severe chronic pain. NTII has 3 products in development: Corticotropin, an anti-inflammatory drug; Dynorphin A, a reducer of morphine dependence; and Nicosim, an aid to stop nicotine addiction.
-- hoovers description

Anyone know this company?

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
1494	BVF sells out here...	mopgcw	-	10/23/2009
1493	Neurobiological Technologies Announces Suspension of Viprinex Development *	sim1	-	1/13/2009
1492	<i> that calls for the Board of Directors to fulfill "its fiduciary d	Steve Lokness	-	12/24/2008
1491	The stock was up sharply on this news: BVF Partners: Neurobiological Technologi	JMarcus	-	12/24/2008
1490	It is too bad, and I give them kudos for sheperding this one over a bumpy life w	mopgcw	-	12/18/2008
1489	Too bad. It was a long shot, but the risk/reward ratio looked pretty good to me	JMarcus	-	12/18/2008
1488	Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futili	sim1	-	12/17/2008
1487	The stock sure took a beating on today's news, but the volume wasn't lar	JMarcus	-	12/16/2008
1486	Neurobiological Technologies' Partner, Celtic Pharma, Provides Update on XER	sim1	-	12/16/2008
1485	FYI, JP Morgan dumped a bunch of shares. Thanks much for the summary -- most a	mopgcw	-	11/18/2008
1484	I missed last year's annual stockholders meeting of NTII, but I was back in	JMarcus	2	11/17/2008
1483	Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financ	mopgcw	-	11/8/2008
1482	a couple small insider buys...	mopgcw	-	10/30/2008
1481	a small insider buy recorded by Stuppin...	mopgcw	-	10/16/2008
1480	Thanks for clarifying.	ghmm	-	10/13/2008
1479	No, intent would be to run a 2nd trial with a partner.	rkrw	-	10/13/2008
1478	I didn't catch the call but if they are going from 2 trials to 1 does it mea	ghmm	-	10/13/2008
1477	Funny to call it a game changer. More like now if it fails, they'll have som	rkrw	-	10/13/2008
1476	That is the best I can figure. As quoted in the most recent PR "this is a	mopgcw	-	10/13/2008
1475	Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Pha	sim1	-	10/13/2008
1474	It's a futility analysis. I suppose stop the trial or keep going. Phase 3	rkrw	-	10/11/2008
1473	Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Tria	mopgcw	-	10/11/2008
1472	Neurobiological Technologies Announces Amendment of License and Cooperation Agre	sim1	-	2/26/2008
1471	Neurobiological Technologies Reports Second Quarter Financial Results Monday Feb	mopgcw	-	2/11/2008
1470	Try it now I just read the PR [below]. I've noticed that empty document/ex	ghmm	-	12/5/2007

Go to reply# or date (mm/dd/yy):